Samenvatting
Background: With the current trend in healthcare moving towards a more value-based approach, it is essential to understand what value encompasses. Objectives: To develop an actionable value-based outcome set (VOS) for daily practice. Methods: A mixed method approach was used consisting of four phases. Formerly, a systematic review was conducted, providing an overview of all patient-relevant outcomes defined in current literature. These 23 outcomes were then presented to a group of patients, using a modified nominal group technique (NGT), to establish whether these results represented all of their relevant outcomes. Subsequently, these outcomes were ranked according to importance by patients attending our academic specialized psoriasis clinic. A review of the literature was performed to assess which instruments were available and suitable to evaluate the outcomes in this VOS. Finally, a pilot feasibility test was performed amongst patients. Results: Of the 23 outcomes, two were omitted from the ranking exercise after the NGT. In the ranking exercise, 120 patients participated. The median age was 50.0 (IQR 25.0) years and 36.7% were female. Median PASI score was 2.4 (IQR 5.2), and treatments varied from topicals to biologicals. The outcomes scored as most important were symptom control, treatment efficacy, confidence in care and control of disease. The least important outcomes were comorbidity control, productivity and cost of care. A significant difference was shown between the ranking of the outcomes (p < 0.001). In total, 12 instruments were selected, which are reported by both patient and provider, to measure the outcomes in this VOS. Median completion time for the patient part was 30 min (IQR 2.8). Conclusions: This VOS is a first proposal to evaluate psoriasis care in a value-based manner. Measuring these outcomes can enable us to critically appraise and improve current care processes, within the reality of available resources, thereby increasing value for patients.
Originele taal-2 | English |
---|---|
Pagina's (van-tot) | 528-539 |
Aantal pagina's | 12 |
Tijdschrift | Journal of the European Academy of Dermatology and Venereology |
Volume | 37 |
Nummer van het tijdschrift | 3 |
Vroegere onlinedatum | 16 nov 2022 |
DOI's | |
Status | Published - mrt 2023 |
Bibliografische nota
Funding Information:The research activities of NH and ED are funded by a Novartis Research Collaboration Agreement and a chair ‘Value In Psoriasis’ from Janssen‐Cilag, respectively. The research activities of IH and NvG are supported by the Scientific Research Foundation‐Flanders (FWO junior postdoctoral mandate: 12Y2420N, FWO senior clinical investigator: 1831512N respectively).
Publisher Copyright:
© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Copyright:
Copyright 2022 Elsevier B.V., All rights reserved.